[go: up one dir, main page]

KR20230009682A - A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient - Google Patents

A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient Download PDF

Info

Publication number
KR20230009682A
KR20230009682A KR1020210090389A KR20210090389A KR20230009682A KR 20230009682 A KR20230009682 A KR 20230009682A KR 1020210090389 A KR1020210090389 A KR 1020210090389A KR 20210090389 A KR20210090389 A KR 20210090389A KR 20230009682 A KR20230009682 A KR 20230009682A
Authority
KR
South Korea
Prior art keywords
coffee beans
cordycepin
mushroom
roasting
green coffee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020210090389A
Other languages
Korean (ko)
Inventor
유연혁
유화진
유현진
Original Assignee
유화진
유현진
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유화진, 유현진 filed Critical 유화진
Priority to KR1020210090389A priority Critical patent/KR20230009682A/en
Publication of KR20230009682A publication Critical patent/KR20230009682A/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23FCOFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F5/00Coffee; Coffee substitutes; Preparations thereof
    • A23F5/02Treating green coffee; Preparations produced thereby
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23FCOFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F2200/00Special features
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 종균으로부터 선택되는 어느 하나 이상의 종균을 커피 생두에 접종 발효하여 코디세핀이 현저하게 증진된 커피 생두를 제조한 다음 이 생두를 추출하여 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 코디세핀을 함유하는 추출물을 제조할 수 있으며, 기본 베이스가 커피이기 때문에 코디세핀을 함유하는 음료 형태로 공급이 가능하여 산업화 및 상업화에 매우 유용하다.In the present invention, green coffee beans with markedly enhanced cordycepin are prepared by inoculating and fermenting green coffee beans with at least one spawn selected from spawns consisting of Ganoderma lucidum, Phellinus elegans, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis, and then extracting the green coffee beans. extract containing cordycepin showing antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects can be prepared, and since the basic base is coffee, it can be supplied in the form of a beverage containing cordycepin, which is very suitable for industrialization and commercialization. useful.

Description

항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 커피와 버섯 균주를 활용한 신규한 코디세핀 제조방법 및 이 제조방법에 의해 생산된 코디세핀 함유 추출물을 활성성분으로 하는 조성물{A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient}A novel method for preparing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects, and a composition containing cordycepin-containing extract produced by the manufacturing method as an active ingredient {A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient}

본 발명은 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 커피와 버섯 균주를 활용한 신규한 코디세핀 제조방법 및 이 제조방법에 의해 생산된 코디세핀 함유 추출물을 활성성분으로 하는 조성물에 관한 것이다.The present invention relates to a novel method for preparing cordycepin using coffee and mushroom strains exhibiting antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects, and a composition containing cordycepin-containing extract produced by the manufacturing method as an active ingredient. will be.

코디세핀(cordycepin)은 1950년 쿠닝햄(Cunningham) 등에 의해 밝혀진 이후, 약리 활성에 관해 많은 연구가 이루어졌으며. 이와 같은 코디세핀은 m-RNA의 합성을 저해하고 항균, 항진균, 면역증강 및 항암효과가 있는 것으로 주로 알려져 있다(Nature, 166, 949~954, 1950; Cancer Res., 21, 216~220, 1961 ; Biochem. Biophys. Acta., 80, 640~647, 1964).Since cordycepin was discovered by Cunningham et al. in 1950, many studies have been conducted on its pharmacological activity. Such cordycepin inhibits m-RNA synthesis and is mainly known to have antibacterial, antifungal, immune enhancing and anticancer effects (Nature, 166, 949~954, 1950; Cancer Res., 21, 216~220, 1961 (Biochem. Biophys. Acta., 80, 640-647, 1964).

최근에는 코디세핀의 혈소판 응집억제 작용에 대한 연구가 많이 진행되고 있는데, 이에 대한 예로, 한국등록특허 제10-464876호에서는 동충하초의 코디세핀을 함유하는 항혈전제 조성물이 개시되어 있다. Recently, many studies on the platelet aggregation inhibitory action of cordycepin have been conducted. As an example of this, Korean Patent Registration No. 10-464876 discloses an antithrombotic composition containing cordycepin of Cordyceps sinensis.

그리고 코디세핀 성분을 분리 정제하는 방법으로서, 한국공개특허 제10-2001-0054264호에 동충하초로부터 분리 추출된 항암제용 코디세핀과 그 제조방법이 개시되어 있는데, 이 방법은 동충하초 버섯의 기주와 자실체의 건체를 메탄올로 열탕추출 한 후, 여과하여 메탄올추출물을 제조하고 상기 메탄올 추출물을 Hexane, Chloroform, Ethyl acetate, Buthanol, Water층으로 분획을 실시한 후, 각 분획에 대하여 검정을 실시하여 활성을 나타낸 분획에 대하여 실리카겔 컬럼상에서 클로로포름-메탄올로 용리시킨 다음, 이를 prep HPLC로 정제하고 메탄올-물(2:8)을 사용하여 활성 peak를 얻은 후 이에 대해서 검정을 실시하고 이 부위만을 계속해서 분리하는 것으로 구성되어 있다.In addition, as a method for separating and purifying cordycepin components, Korean Patent Publication No. 10-2001-0054264 discloses cordycepin for anticancer drugs separated and extracted from Cordyceps sinensis and a method for producing the same. After extracting the dried body with methanol in hot water, filtering to prepare a methanol extract, and the methanol extract was fractionated into Hexane, Chloroform, Ethyl acetate, Buthanol, and Water layers, and then assayed for each fraction to obtain an active fraction. It consists of eluting with chloroform-methanol on a silica gel column, purifying it with prep HPLC, obtaining an active peak using methanol-water (2:8), performing assay on it, and continuing to separate only this part. there is.

또한, 한국공개특허 제10-2017-0049353호에는 동충하초로부터 고순도의 코디세핀을 신속하게 추출하는 방법이 개시되어 있는데, 이 방법은 동충하초로부터 동충하초 추출물을 추출하는 단계; 상기 동충하초 추출물을 다공성 겔 컬럼 크로마토그래피를 통과시켜 코디세핀 분획을 얻는 단계; 및 상기 코디세핀 분획을 실리카겔 컬럼 크로마토그래피를 통해 정제한 후 재결정하여 코디세핀을 얻는 단계를 포함하고 있다.In addition, Korean Patent Publication No. 10-2017-0049353 discloses a method for rapidly extracting high-purity cordycepin from Cordyceps sinensis, which includes the steps of extracting Cordyceps sinensis extract from Cordyceps sinensis; Passing the cordyceps extract through porous gel column chromatography to obtain a cordycepin fraction; and purifying the cordycepin fraction through silica gel column chromatography, followed by recrystallization to obtain cordycepin.

그러나 상술한 방법은 동충하초만을 활용하고 있어 산업화, 상업화 및 우리가 자주 마시는 음료 형태로 제조하는데에 한계를 가지고 있다. However, the above-described method uses only Cordyceps sinensis, so it has limitations in industrialization, commercialization, and manufacturing in the form of beverages that we often drink.

1. 한국등록특허 제10-464876호1. Korean Patent Registration No. 10-464876 2. 한국공개특허 제10-2001-0054264호2. Korean Patent Publication No. 10-2001-0054264 3. 한국공개특허 제10-2017-0049353호3. Korean Patent Publication No. 10-2017-0049353

따라서 본 발명이 이루고자 하는 과제는 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 커피와 버섯 균주를 활용한 신규한 코디세핀 제조방법 및 이 제조방법에 의해 생산된 코디세핀 함유 추출물을 활성성분으로 하는 조성물을 제공하는 것이다.Therefore, the problem to be achieved by the present invention is a novel method for preparing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects, and a cordycepin-containing extract produced by the manufacturing method as an active ingredient It is to provide a composition that

상기 기술적 과제를 달성하기 위하여 본 발명은In order to achieve the above technical problem, the present invention

영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균을 커피 생두에 접종하여 발효시키는 단계; 및Inoculating green coffee beans with at least one spawn selected from the group consisting of Ganoderma lucidum, Phellinus elegans, chaga, zinnia and cordyceps and fermenting them; and

용매를 물 또는 에탄올로 하여 상기 발효 생두를 추출하는 단계를 포함하는 것을 특징으로 하는 커피와 버섯 균주를 활용한 신규한 코디세핀 함유 추출물 제조방법을 제공한다.Provided is a novel method for producing a cordycepin-containing extract using coffee and mushroom strains, comprising the step of extracting the fermented green coffee beans using water or ethanol as a solvent.

상술한 바와 같은 본 발명에 따른 제조방법에 있어서, 상기 커피 생두는 발아시킨 것일 수 있다.In the manufacturing method according to the present invention as described above, the green coffee beans may be germinated.

상술한 바와 같은 본 발명에 따른 제조방법에 있어서, 상기 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균은 효모균에 접종을 한 후에 20 내지 40℃에서 70 내지 170시간 배양한 것일 수 있다.In the manufacturing method according to the present invention as described above, any one or more spawn selected from the group consisting of Ganoderma lucidum, Phellinus linteus, Chaga mushroom, Cinnamon mushroom, and Cordyceps sinensis is inoculated with yeast and then heated to 70 °C at 20 to 40 ° C. It may be cultured for 170 hours.

상술한 바와 같은 본 발명에 따른 제조방법에 있어서, 상기 발효는 상기 발효는 온도 20 내지 45℃, 습도 35 내지 70%에서 12 내지 120시간 동안 상기 커피 생두에 접종된 복합 종균을 배양하는 것일 수 있다.In the manufacturing method according to the present invention as described above, the fermentation may be performed by culturing the complex spawn inoculated into the green coffee beans at a temperature of 20 to 45 ° C. and a humidity of 35 to 70% for 12 to 120 hours. .

상술한 바와 같은 본 발명에 따른 제조방법은 추출단계 전에 상기 커피 생두를 로스팅하는 단계를 더 포함할 수 있다.As described above, the manufacturing method according to the present invention may further include roasting the green coffee beans before the extraction step.

또한, 본 발명은 다른 기술적 과제를 달성하기 위하여, 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균이 접종 발효되어 코디세핀 함량이 증진된 커피 생두 및 이를 로스팅한 커피 원두를 제공한다.In addition, the present invention, in order to achieve another technical problem, green coffee beans with increased cordycepin content by inoculation and fermentation of one or more seed fungi selected from the group consisting of Ganoderma lucidum, Sanghwang mushroom, chaga mushroom, zinnia mushroom and cordyceps sinensis, and green coffee beans containing the same They serve roasted coffee beans.

또 다른 기술적 과제를 달성하기 위하여, 본 발명은 상술한 바와 같이 제조된 코디세핀을 다량 함유하는 커피 생두 또는 커피 원두를 추출한 추출물을 활성성분으로 하여 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 조성물을 제공한다.In order to achieve another technical problem, the present invention has antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects by using green coffee beans or an extract extracted from coffee beans containing a large amount of cordycepin prepared as described above as an active ingredient. Provides a visible composition.

본 발명은 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 종균으로부터 선택되는 어느 하나 이상의 종균을 커피 생두에 접종 발효하여 코디세핀이 현저하게 증진된 커피 생두를 제조한 다음 이 생두를 추출하여 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 코디세핀을 함유하는 추출물을 제조할 수 있으며, 기본 베이스가 커피이기 때문에 코디세핀을 함유하는 음료 형태로 공급이 가능하여 산업화 및 상업화에 매우 유용하다.The present invention inoculates green coffee beans with at least one spawn selected from spawns consisting of Ganoderma lucidum, Phellinus linteus, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis, prepares green coffee beans with markedly enhanced cordycepin, and then extracts the green coffee beans. extracts containing cordycepin showing antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects can be prepared, and since the basic base is coffee, it can be supplied in the form of a beverage containing cordycepin, which is very suitable for industrialization and commercialization. useful.

본 발명에 따른 조성물을 복용하는 경우 함량이 증진된 코디세핀에 의해 인간 정상 세포의 면역기능을 활성화하여 암세포의 증식과 재발을 억제하고 혈소판 응집 억제를 통한 항혈전, 항균, 항진균 효과를 얻을 수 있으며, 부수적으로 부드러운 초콜릿 향에 돋보이는 카카오향, 연하고 깊고 풍부한 맛과 향을 느낄 수 있는 장점이 있다.When the composition according to the present invention is taken, the immune function of human normal cells is activated by the increased cordycepin content to inhibit the proliferation and recurrence of cancer cells, and antithrombotic, antibacterial, and antifungal effects can be obtained through inhibition of platelet aggregation, , Incidentally, it has the advantage of being able to feel the cacao scent that stands out with the soft chocolate scent, and the soft, deep and rich taste and aroma.

도 1은 본 발명에 따른 커피 생두 제조 방법에 대한 흐름도이다.
도 2 내지 7은 본 발명에 따라 5종 버섯 복합 종균 접종 후 배양 상태를 시간에 따라 커피 생두 사진이다.
1 is a flowchart of a method for manufacturing green coffee beans according to the present invention.
2 to 7 are photographs of green coffee beans over time in culture after inoculation with 5 types of mushroom composite spawn according to the present invention.

이하, 본 발명을 실시하기 위한 구체적 내용을 첨부 도면을 참조하여 상세하게 설명하기로 한다.Hereinafter, specific details for carrying out the present invention will be described in detail with reference to the accompanying drawings.

본 발명은 일차적으로 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 코디세핀의 함량이 증진된 커피 생두를 제조할 수 있는 방법을 제공하며, 이에 따라 제조된 커피 생두, 이 생두를 이용한 추출물, 이 생두를 로스팅하여 제조되는 커피 원두와 커피 원두를 이용한 추출물을 제공한다. 따라서, 코디세핀의 함량이 증진된 커피 생두 제조방법을 도 1을 참조하여 우선적으로 설명하기로 한다.The present invention provides a method for producing green coffee beans with increased cordycepin content, which primarily shows antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects, and green coffee beans prepared thereby, and an extract using the green coffee beans , Coffee beans prepared by roasting the green beans and extracts using the coffee beans are provided. Accordingly, a method for manufacturing green coffee beans having an increased cordycepin content will be first described with reference to FIG. 1 .

도 1은 본 발명에 따른 코디세핀 함량이 증진된 본 발명에 따른 커피 생두 제조 방법에 대한 흐름도로서 먼저 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 버섯 복합 종균에 대하여 설명하기로 한다.1 is a flowchart of a method for manufacturing green coffee beans according to the present invention in which the content of cordycepin is increased according to the present invention. First, complex mushroom spawns composed of Ganoderma lucidum, Phellinus linteus, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis will be described. .

코디세핀 함량이 증진된 커피 생두를 제조하는 방법을 다양하게 연구한 끝에 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 종균으로부터 선택되는 어느 하나 이상의 종균을, 특히 바람직하게는 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초의 5종 버섯 복합 종균을 사용하는 것이 생두에서 유효하게 배양 발효되어 코디세핀의 함량을 현저하게 증진시키는 것을 확인하여 본 발명에 적용한 것이다.After various studies on methods for producing green coffee beans with increased cordycepin content, one or more spawners selected from the group consisting of Ganoderma lucidum, Sanghwang mushroom, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis are selected, particularly Ganoderma lucidum, It was applied to the present invention after confirming that the use of 5 types of mushroom composite spawn fungi of Phellinus Phellinus, chaga, zinnia and cordyceps was effectively cultured and fermented in green beans to significantly increase the cordycepin content.

상기 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 5종 버섯 종균은 영지버섯 균사체, 상황버섯 균사체, 차가버섯 균사체, 꽃송이버섯 균사체 및 동충하초 균사체를 배양 배지에 각각 또는 2종 이상을 동시에 혼합하여 배양하여 얻어지는 것으로 가장 바람직한 것은 배양 단계에서부터 5종을 혼합하여 복합 배양하는 것이 바람직하며, 5종을 복합 배양할 때 이들의 비율은 특별한 제한이 없으나 바람직하게는 영지버섯 균사체 100중량을 기준으로 다른 균사체는 30 내지 150중량일 수 있다(S100). The five types of mushroom spawn consisting of Ganoderma lucidum, Phellinus lucidum, Chaga mushroom, Zinnia mushroom, and Cordyceps mycelium are each or two or more species simultaneously Most preferably, it is obtained by mixing and culturing, and it is preferable to mix and culture 5 species from the culture step, and when the 5 species are combined, there is no particular restriction on their ratio, but preferably based on 100 weight of ganoderma lucidum mycelium Other mycelium may be 30 to 150 weight (S100).

즉 2종 이상을 복합 배양할 때는 하나의 균사체 100중량을 기준으로 다른 균체를 30 내지 150중량을 혼합하여 배양하는 것이 바람직하다. That is, when culturing two or more species in a complex, it is preferable to culture by mixing 30 to 150 weight of other mycelium based on 100 weight of one mycelium.

또한, 본 발명에서는 배양하여 얻어진 상 버섯 종균을 커피 생두에 직접 접종하여 배양 발효할 수 있으나, 코디세핀의 함량을 더욱 증진하고 원활한 배양 발효를 위하여 효모균에 버섯 종균을 접종하여 배양 배지에서 20 내지 40℃에서 70 내지 170시간 배양한 것을 사용하는 것이 바람직하다.In addition, in the present invention, the mushroom spawn obtained by culturing can be directly inoculated into green coffee beans for culture and fermentation, but in order to further enhance the content of cordycepin and facilitate culture and fermentation, yeast is inoculated with mushroom spawn, and 20 to 40 It is preferable to use those cultured for 70 to 170 hours at ° C.

상기 버섯 종균의 배양방법의 배양 온도, 배양 배지, 진탕 속도 및 배양기간 등 본 발명이 속하는 기술 분양 널리 알려진 것이라면 특별한 제한 없이 이용이 가능하며, 배양 배지의 예를 들면 질소원과 무기질 원이 풍부한 배지에서 활발한 생육을 보이는바, MCM 배지 또는 YMPG 배지에서 배양할 수 있다. Any widely known technique to which the present invention belongs, such as the culture temperature, culture medium, shaking speed, and culture period of the method of culturing the mushroom spawn, can be used without particular limitation, and the culture medium, for example, in a medium rich in nitrogen and mineral sources Since it shows vigorous growth, it can be cultured in MCM medium or YMPG medium.

이어서 커피 생두에서 잔류농약, 이물질을 제거하는 세척 및 생두 멸균하는데(S200), 커피 생두의 세척 및 멸균의 방법 내지 조건은 본 발명이 속하는 기술에 분야에서 널리 알려진 것이라면 특별한 제한이 없이 이용 가능하다.Next, washing and sterilization of green coffee beans to remove residual pesticides and foreign substances from green coffee beans and sterilization of green coffee beans (S200). Methods and conditions for washing and sterilizing green coffee beans may be used without particular limitation as long as they are widely known in the art to which the present invention belongs.

다음으로, S 200에서 세척 멸균한 커피 생두에 상기 5종 버섯 복합 종균을 접종한다(S 300). 이때 종균의 접종은 각 버섯의 종균이 액상으로 되어 있으므로 포트(200ml 또는 500ml)에 커피 생두와 종균을 넣어 쉐이킹(shaking) 함으로써 접종된다. 커피 생두와 버섯의 종균의 중량비는 특별한 제한이 없으나 1:0.05~0.30인 것이 바람직하다.Next, the green coffee beans washed and sterilized in S 200 are inoculated with the composite spawn of the 5 types of mushrooms (S 300). At this time, inoculation of spawn is inoculated by shaking green coffee beans and spawn in a pot (200ml or 500ml) since the spawn of each mushroom is in liquid form. The weight ratio of green coffee beans and mushroom spawn is not particularly limited, but is preferably 1:0.05 to 0.30.

또한, 본 발명에서는 코디세핀 함량 증가의 효율성을 높이기 위하여 커피 생두를 발아한 후에 버섯 종균을 접종할 수 있는데, 발아 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한이 없으며, 커피 생두와 물의 중량비를 1:1.0~2.5로 하여 3시간 내지 5시간 동안 36 내지 68℃에서 침지하여 발아시키는 방법을 예로 들 수 있다.In addition, in the present invention, in order to increase the efficiency of increasing the cordycepin content, mushroom spawn can be inoculated after germinating green coffee beans. The germination method is not particularly limited as long as it is widely known in the art to which the present invention belongs. An example is a method of soaking at a weight ratio of 1:1.0 to 2.5 at 36 to 68° C. for 3 to 5 hours to germinate.

마지막으로, 버섯 종균이 접종된 커피 생두를 배양 발효 후 건조하게 되면(S 400), 본 발명에 따른 코디세핀이 현저하게 증가한 커피 생두 제조방법은 완료된다.Finally, when the green coffee beans inoculated with the mushroom spawn are cultured and fermented and then dried (S 400), the manufacturing method of green coffee beans with significantly increased cordycepin according to the present invention is completed.

상기 배양 발효는 접종한 커피 생두를 발효기에 넣고 온도 20 내지 45℃, 습도 35 내지 70%에서 12 내지 120시간 동안 실시하는 것이 바람직하며, 배양 발효를 시작하여 대략 12 내지 24시간 후부터 시큼한 발효된 식초 향이 올라오며 커피 생두 표면에 버섯 균주가 착상하는 것을 육안으로 확인이 가능하며, 커피 생두 표면에 배양된 버섯 균주가 피어나고 시큼한 발효된 식초 향이 강하게 올라오면 발효를 멈추면 되며 이때까지의 시간이 12 내지 120시간까지 다양한 폭으로 소요될 수 있다.The culture fermentation is preferably carried out for 12 to 120 hours at a temperature of 20 to 45 ° C. and a humidity of 35 to 70% by putting the inoculated green coffee beans in a fermenter, and sour fermented vinegar begins about 12 to 24 hours after the start of the culture fermentation. It is possible to visually confirm that the mushroom strain is implanted on the surface of green coffee beans with the aroma rising, and when the cultured mushroom strain blooms on the surface of green coffee beans and a strong scent of sour fermented vinegar rises, stop fermentation. It may take a wide range of time.

상술한 배양 발효의 예로서 발아된 커피 생두에 20중량%의 5종 복합 버섯 종균을 접종한 후에 발효기에 넣고 온도 25℃, 습도 60%에서 배양 발효하여 버섯 균주가 피어나는 상태에 사진을 도 2 내지 도 7에 나타냈다.As an example of the culture fermentation described above, after inoculating germinated green coffee beans with 20% by weight of 5 types of composite mushroom spawn, they were placed in a fermentor and cultured and fermented at a temperature of 25 ° C and a humidity of 60%, and a photograph of the mushroom strain blooming is shown in FIG. 2 to Figure 7.

상술한 바와 같이 제조된 커피 생두를 추출하면 본 발명에 따른 추출 조성물을 제조할 수 있으며, 또는 커피 생두를 로스팅하여 제조한 커피 원두를 추출하여 제조할 수 있는데, 이를 로스팅 방법 내지 추출 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한이 없으며, 물 또는 에탄올을 용매로 추출하는 것이 바람직하다.The extraction composition according to the present invention can be prepared by extracting the green coffee beans prepared as described above, or it can be prepared by extracting the coffee beans prepared by roasting the green coffee beans. There is no particular limitation as long as it is widely known in the art, and it is preferable to extract water or ethanol as a solvent.

이하 실시예와 실험예를 통하여 본 발명을 상세하게 설명하기로 한다.The present invention will be described in detail through examples and experimental examples below.

<< 실시예Example 1> 1>

영지버섯 균사체, 상황버섯 균사체, 차가버섯 균사체, 꽃송이버섯 균사체 및 동충하초 균사체를 동일 중량 비율로 하여 MCM 배지에 동시에 혼합한 후 23℃에서 168시간 동안 복합 배양하여 얻어진 5종 버섯 복합 종균을 세척 멸균한 커피 생두와 함께 포트에 넣어 쉐이킹(shaking)하여 접종하였다. 이때 커피 생두와 5종 버섯 복합 종균의 중량비는 1:0.2이었다.Ganoderma lucidum mycelium, Sanghwang mushroom mycelium, Chaga mushroom mycelium, Zinnia mushroom mycelium and Cordyceps mycelium were mixed in MCM medium at the same weight ratio, and then 5 types of mushroom composite spawn obtained by complex culture at 23 ° C for 168 hours were washed and sterilized. It was inoculated by putting it in a pot together with green coffee beans and shaking. At this time, the weight ratio of green coffee beans and 5 types of mushroom composite spawn was 1:0.2.

이어서 발효기에 온도 29℃~39℃, 습도 46~60%에서 배양 발효하여 버섯 균주가 피어나는 상태를 확인하여 발효를 종료하였으며, 종료 때까지 총 발효 시간은 120시간 이었다.Subsequently, fermentation was terminated by culturing and fermenting in a fermentor at a temperature of 29 ° C to 39 ° C and a humidity of 46 to 60% to confirm the blooming of the mushroom strain, and the total fermentation time until termination was 120 hours.

<< 실시예Example 2> 2>

실시예 1과 동일하며 다만 커피 생두를 멸균한 후에 커피 생두와 물의 중량비를 1:2로 하여 3시간~5시간 동안 36℃ 내지 68℃에서 침지하여 발아시킨 것을 사용하여 5종 버섯 복합 종균을 접종한 것에 차이가 있다.Same as in Example 1, except that after sterilizing green coffee beans, the weight ratio of green coffee beans and water was 1:2, and soaked at 36 ° C to 68 ° C for 3 to 5 hours to germinate. Inoculation of 5 types of mushroom composite spawn There is a difference in what

<< 실시예Example 3> 3>

상기 실시예 1과 동일하며 다만 배양한 효모균에 5종 버섯 복합 종균을 접종하여 36℃에서 168시간 동안 배양하여 커피 생두에 접종한 것에 차이가 있다.It is the same as in Example 1, except that the cultured yeast was inoculated with 5 types of mushroom composite spawn, cultured at 36 ° C for 168 hours, and inoculated into green coffee beans.

<< 실시예Example 4> 4>

실시예 1과 동일하며 영지버섯 균사체만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only Ganoderma lucidum mycelium was used.

<< 실시예Example 5> 5>

실시예 1과 동일하며 상황버섯 균사체만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only Sanghwang mushroom mycelium was used.

<< 실시예Example 6> 6>

실시예 1과 동일하며 차가버섯 균사체만을 사용한 것에 차이가 있다.It is the same as Example 1, and there is a difference in that only the mycelium of the chaga mushroom was used.

<< 실시예Example 7> 7>

실시예 1과 동일하며 꽃송이버섯 균사체만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only the mushroom mycelium was used.

<< 실시예Example 8> 8>

실시예 1과 동일하며 동충하초 균사체만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only Cordyceps sinensis mycelium was used.

<< 실시예Example 9> 9>

실시예 1과 동일하며 영지버섯 균사체. 상황버섯 균사체 및 동충하초 균사체 3종만을 사용한 것에 차이가 있다.Same as Example 1, ganoderma lucidum mycelium. There is a difference in using only three types of mycelium of Phellinus Phellinus and cordyceps mycelium.

<< 실시예Example 10> 10>

실시예 1과 동일하며 상황버섯 균사체, 차가버섯 균사체 및 꽃송이버섯 균사체 3종만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only three types of mycelium of Phellinus linteus, mycelium of Chaga mushroom, and mushroom mycelium were used.

<< 실시예Example 11> 11>

실시예 1과 동일하며 영지버섯 균사체, 차가버섯 균사체 및 동충하초 균사체 3종만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only three types of ganoderma lucidum mycelium, chaga mushroom mycelium, and cordyceps mycelium were used.

<< 실시예Example 12> 12>

실시예 1과 동일하며 영지버섯 균사체, 상황버섯 균사체, 차가버섯 균사체, 및 동충하초 균사체 4종만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only four types of ganoderma lucidum mycelium, mycelium of Sanghwang mushroom, mycelium of chaga mushroom, and mycelium of Cordyceps sinensis were used.

<< 실시예Example 13> 13>

실시예 1과 동일하며 영지버섯 균사체, 상황버섯 균사체, 차가버섯 균사체, 및 꽃송이 버섯 균사체 4종만을 사용한 것에 차이가 있다.It is the same as in Example 1, and there is a difference in that only four types of ganoderma lucidum mycelium, mycelium of Sanghwang mushroom, mycelium of chaga mushroom, and mycelium of cauliflower mushroom were used.

<< 시험예test example 1: One: 로스팅roasting 원두 추출물의 코디세핀 함량 측정> Determination of Cordycepin Content in Bean Extract>

상기 실시예의 커피 생두를 건조한 후에 90℃ ~ 189℃ 21분, 189℃~ 198℃ 2분의 저온 로스팅하여 원두를 제조한 후 이를 분쇄하여 원두 분말을 제조하여 제조한 원두 분말에 대하여 코디세핀 함량을 측정하였다. 그 결과를 표 1에 나타냈으며, 대조군으로 동충하초 에탄올 추출물을 다공성 겔 컬럼 크로마토그래피를 통과시켜 얻은 분획을 사용하였다.After drying the green coffee beans of the above example, the coffee beans were roasted at a low temperature of 90 ° C to 189 ° C for 21 minutes and 189 ° C to 198 ° C for 2 minutes to prepare beans, and then ground to prepare coffee bean powder. measured. The results are shown in Table 1, and the fraction obtained by passing the ethanol extract of Cordyceps sinensis through porous gel column chromatography was used as a control.

코디세핀의 함량은 HPLC를 이용하여 다음과 같이 분석하였다.The content of cordycepin was analyzed using HPLC as follows.

기기 : Waters (Waters e2695 module, Waters 2998 PDA)Device: Waters (Waters e2695 module, Waters 2998 PDA)

컬럼 : Waters Spherisorb?? 10㎛ ODS2 컬럼 (4.6 × 250㎜ Analytical)Column: Waters Spherisorb?? 10㎛ ODS2 column (4.6 × 250㎜ Analytical)

유속 : 1㎖/minFlow rate: 1 ml/min

파장 : 254㎚Wavelength: 254nm

이동상 : 0.01M KH2PO4의 15% 메탄올Mobile phase: 0.01M KH2PO4 in 15% methanol

코디세핀 함량(mg/g)Cordycepin content (mg/g) 대조군control group 0.00120.0012 실시예 1Example 1 12.312.3 실시예 2Example 2 14.714.7 실시예 3Example 3 16.216.2 실시예 4Example 4 5.85.8 실시예 5Example 5 5.95.9 실시예 6Example 6 5.65.6 실시예 7Example 7 5.85.8 실시예 8Example 8 5.95.9 실시예 9Example 9 7.57.5 실시예 10Example 10 7.87.8 실시예 11Example 11 8.18.1 실시예 12Example 12 10.710.7 실시예 13Example 13 10.910.9

상기 표 1의 결과를 보면 대조군과 비교하여 현저하게 코디세핀 함량이 증가한 것을 확인할 수 있었으며, 특히 5종의 복합 종균을 이용한 실시예에서 코디세핀의 함량 차이가 매우 크다는 것을 알 수 있었습니다.Looking at the results in Table 1 above, it was confirmed that the content of cordycepin significantly increased compared to the control group. In particular, it was found that the difference in the content of cordycepin was very large in the example using 5 types of complex spawn.

<< 시험예test example 2: 원두 추출물의 향 및 맛 평가> 2: Flavor and taste evaluation of bean extract>

시험예 1에서 사용한 커피 원두 분말과 동일한 분말을 이용하여 추출물을 제조한 후 관능검사 패널로는 해당 분야에 경험이 많은 숙련된 10명(20~30대 남자 5, 여자 5)을 모집하였고, 5점 척도법에 따라 탄맛, 쓴맛, 신맛 및 뒷맛과 바디감 등에 대한 종합 평가를 조사하여 그 결과를 표 2에 나타냈다. 대조군은 아무 처리도 하지 커피 생두를 시험예 1과 동일하게 로스팅하여 사용하였다.After preparing the extract using the same powder as the coffee bean powder used in Test Example 1, 10 experienced people (5 males and 5 females in their 20s and 30s) with a lot of experience in the field were recruited as a sensory test panel. According to the point scale method, a comprehensive evaluation of burnt taste, bitter taste, sour taste, aftertaste, and body was investigated, and the results are shown in Table 2. As a control group, green coffee beans without any treatment were roasted and used in the same manner as in Test Example 1.

관능 종합 평가Sensory Comprehensive Assessment 대조군control group 2.42.4 실시예 1Example 1 4.14.1 실시예 2Example 2 4.44.4 실시예 3Example 3 4.94.9 실시예 4Example 4 3.23.2 실시예 5Example 5 3.23.2 실시예 6Example 6 3.13.1 실시예 7Example 7 3.23.2 실시예 8Example 8 3.53.5 실시예 9Example 9 3.33.3 실시예 10Example 10 3.43.4 실시예 11Example 11 3.43.4 실시예 12Example 12 3.83.8 실시예 13Example 13 3.83.8

상기 표 2의 결과에서도 본 발명에 따른 추출물에서 우수한 평가를 확인할 수 있었으며, 특히 본 발명에 추출물에 대해서는 부드러운 초콜릿 향에 돋보이는 카카오향, 연하고 깊고 풍부한 맛과 향을 느낄 수 있는 종합 평가를 내렸다.Even in the results of Table 2, it was confirmed that the extract according to the present invention was evaluated excellently, and in particular, for the extract according to the present invention, a comprehensive evaluation was given to feel the cacao flavor, soft, deep and rich taste and aroma that stands out in the soft chocolate flavor.

<시험예 3: HepG2 및 HeLa 세포주를 이용한 항암 효과 평가><Test Example 3: Evaluation of anticancer effect using HepG2 and HeLa cell lines>

상기 실시예의 커피 생두를 건조한 후 열수 추출한 추출물과 상기 실시예의 커피 생두를 건조한 후 90℃ ~ 189℃ 21분, 189℃~ 198℃ 2분의 저온 로스팅하여 원두를 열수 추출물의 항암 효과를 알아보기 위하여 미국 종균협회 ATCC(American Type Culture Collection)사로부터 입수한 인간 자궁 경부암 세포주(haman cervical carnoma cell line)인 HeLa 세포주 및 인간 간암 세포주(Hapatocellular carcinoma cell line)인 HepG2 세포주를 이용하여 세포수준에서의 종양세포 증식 억제 효과를 관찰하였다.After drying the green coffee beans of the above example, the hot water extracted extract and the green coffee beans of the above example were dried, and then roasted at a low temperature of 90 ° C to 189 ° C for 21 minutes and 189 ° C to 198 ° C for 2 minutes to examine the anticancer effect of the hot water extract. Tumor cells at the cellular level using HeLa cell line, a human cervical carnoma cell line, and HepG2 cell line, a human hepatocellular carcinoma cell line, obtained from ATCC (American Type Culture Collection) A proliferation inhibitory effect was observed.

상기 추출물의 종양 세포 증식 억제 효과를 관찰하기 위해서 널리 사용되고 있는 MTT 분석법(MTT assay)을 이용하였다.In order to observe the tumor cell proliferation inhibitory effect of the extract, a widely used MTT assay was used.

HeLa 세포주를 56℃로 불활성화시킨 10% FBS, 1% L-글루타민, 1% 항생제/항균제(10,000U/ml의 페니실린, 25㎍/㎖의 암포테신 D 또는 10mg/㎖의 스트렙토 마이신)가 첨가된 DMEM 배지에서 37℃의 온도로 가습된 5% CO2 상태를 유지하면서 24시간 동안 배양하였다. 다음으로, 1㎖당 1ⅹ105 개의 HeLa 세포를 24웰 배양 플레이트에 접종하고 12시간 동안 배양한 후 부착되지 않은 세포를 멸균 인산 완충액으로 3회 세척하고 상기 추출물을 500㎍/㎖의 농도로 처리한 후 37℃의 온도로 가습된 5% CO2 항온 반응기에서 48시간 배양하였다. 10% FBS, 1% L-glutamine, 1% antibiotics/antimycotics (penicillin at 10,000 U/ml, amphothecin D at 25 μg/ml or streptomycin at 10 mg/ml) were added to HeLa cell line inactivated at 56°C. It was cultured for 24 hours while maintaining a humidified 5% CO2 condition at a temperature of 37°C in DMEM medium. Next, 1ⅹ10 5 HeLa cells per 1 ml were inoculated into a 24-well culture plate, cultured for 12 hours, and unattached cells were washed three times with sterile phosphate buffer, and the extract was treated at a concentration of 500 μg/ml. After 48 hours of culture in a humidified 5% CO 2 constant temperature reactor at a temperature of 37 ℃.

배양이 종료되기 4시간 전에 암세포가 배양되고 있는 각각의 웰에 3-(4,5-디메틸티아졸-2-일)-2,5-디페닐테트라졸리움브로마이드(이하, MTT라 함)(최종농도 0.5㎍/㎖)을 첨가하였다. 다음, 이소프로판올에 염산이 최종 농도 0.04N로 첨가된 용액 100ml를 넣고 약 20분간 실온에서 혼합한 후 ELISA 판독기를 사용하여 550nm 파장에서 흡광도를 측정하였다.4 hours before the end of the culture, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (hereinafter referred to as MTT) was added to each well in which cancer cells were cultured (final concentration 0.5 μg/ml) was added. Next, 100 ml of a solution in which hydrochloric acid was added to a final concentration of 0.04N in isopropanol was added and mixed at room temperature for about 20 minutes, and then absorbance was measured at a wavelength of 550 nm using an ELISA reader.

HepG2 세포에 대해서도 상기 MTT 방법과 동일한 방법으로 실시하여 측정된 암세포의 생존율로부터 종양 세포 증식 억제 효과를 평가하였다. 그 결과는 표 3에 나타냈으며, 대조군은 아무 처리도 하지 않은 건조 생두 추출물과 동일한 조건으로 저온 로스팅한 커피 원두 추출물로 하였다.HepG2 cells were also carried out in the same manner as the above MTT method, and the tumor cell proliferation inhibitory effect was evaluated from the measured cancer cell viability. The results are shown in Table 3, and the control group was a coffee bean extract roasted at a low temperature under the same conditions as the dried green bean extract without any treatment.

HepG2 세포주 생존율(%)HepG2 cell line viability (%) HeLa 세포주 생존율(%)HeLa cell line viability (%) 대조군 생두control green beans 91.2±1.291.2±1.2 89.4±1.189.4±1.1 대조군 로스팅 원두Control roasted beans 91.5±1.391.5±1.3 90.5±0.990.5±0.9 실시예 1 생두Example 1 green beans 24.1±1.324.1±1.3 23.4±1.323.4±1.3 실시예 1 로스팅Example 1 Roasting 24.5±1.224.5±1.2 24.9±1.324.9±1.3 실시예 2 생두Example 2 green beans 20.1±1.320.1±1.3 20.5±1.220.5±1.2 실시예 2 로스팅 Example 2 Roasting 20.8±1.320.8±1.3 21.1±1.321.1±1.3 실시예 3 생두Example 3 Green Beans 17.2±1.117.2±1.1 17.1±1.317.1±1.3 실시예 3 로스팅Example 3 Roasting 17.9±1.317.9±1.3 17.3±1.217.3±1.2 실시예 4 생두Example 4 Green Beans 44.1±1.144.1±1.1 44.3±1.344.3±1.3 실시예 4 로스팅Example 4 Roasting 44.5±1.344.5±1.3 44.8±1.344.8±1.3 실시예 5 생두Example 5 Green Beans 43.9±1.243.9±1.2 43.1±1.143.1±1.1 실시예 5 로스팅Example 5 Roasting 43.9±1.443.9±1.4 43.8±1.343.8±1.3 실시예 6 생두Example 6 Green Beans 44.2±1.344.2±1.3 44.9±1.244.9±1.2 실시예 6 로스팅Example 6 Roasting 44.3±1.244.3±1.2 45.1±1.345.1±1.3 실시예 7 생두Example 7 Green Beans 44.1±1.244.1±1.2 44.9±1.244.9±1.2 실시예 7 로스팅Example 7 Roasting 43.9±1.343.9±1.3 17.9±1.217.9±1.2 실시예 8 생두Example 8 Green Beans 44.4±1.344.4±1.3 17.9±1.217.9±1.2 실시예 8 로스팅 Example 8 Roasting 44.9±1.244.9±1.2 17.9±1.217.9±1.2 실시예 9 생두Example 9 Green Beans 35.1±1.235.1±1.2 35.4±1.335.4±1.3 실시예 9 로스팅Example 9 Roasting 36.7±1.336.7±1.3 36.2±1.136.2±1.1 실시예 10 생두Example 10 Green Beans 36.4±1.236.4±1.2 36.7±1.336.7±1.3 실시예 10 로스팅 Example 10 Roasting 36.9±1.236.9±1.2 37.5±1.237.5±1.2 실시예 11 생두Example 11 Green Beans 34.1±1.334.1±1.3 35.1±1.235.1±1.2 실시예 11 로스팅Example 11 Roasting 34.9±1.134.9±1.1 36.5±1.136.5±1.1 실시예 12 생두Example 12 green beans 31.4±1.331.4±1.3 31.8±1.331.8±1.3 실시예 12 로스팅Example 12 Roasting 32.1±1.132.1±1.1 32.7±1.232.7±1.2 실시예 13 생두 Example 13 Green Beans 30.9±1.130.9±1.1 31.4±1.131.4±1.1 실시예 13 로스팅Example 13 Roasting 30.9±1.230.9±1.2 31.6±1.331.6±1.3

상기 표 3의 결과를 보면 대조군과 비교하여 본 발명의 추출물에서 HepG2 및 HeLa 세포의 암세포주의 생존율이 현격히 감소하여 암세포 생존율이 17~45%에 이르는 것을 확인할 수 있었으며, 복합 종균을 사용할수록 효과가 증가함을 알 수 있었다. 상기 시험 결과로부터 본 발명에 따른 실시예 추출물의 종양 세포 증식 억제효과가 우수함을 알 수 있다.Looking at the results of Table 3, it was confirmed that the survival rate of cancer cell lines of HepG2 and HeLa cells was significantly reduced in the extract of the present invention compared to the control group, and the survival rate of cancer cells reached 17 to 45%, and the effect increased as the complex spawn was used. could know that From the above test results, it can be seen that the tumor cell proliferation inhibitory effect of the example extracts according to the present invention is excellent.

<시험예 4: 시험동물을 이용한 항암 효과 평가><Test Example 4: Evaluation of anticancer effect using test animals>

상기 시험예 3에서 사용한 추출물의 항암 효과를 시험동물 단계에서 검토하였다.The anti-cancer effect of the extract used in Test Example 3 was examined in the test animal stage.

시험동물은 생후 5주된 25~30g의 웅성 Balb/c 마우스를 대한 바이오 링크사로부터 구입하여 사용하였다. 시험 기간 동안 사료와 물은 자유롭게 섭취하도록 하였으며, 동물 시험실의 온도는 22± 1℃, 습도 55± 5%로 유지하였다. 또한, 12시간 마다 낮과 밤이 반복되도록 시험실 내 명암주기(light-dark cycle)를 조절하였다.As test animals, male Balb/c mice, 5 weeks old and weighing 25 to 30 g, were purchased from Daehan Bio Link and used. Feed and water were freely consumed during the test period, and the temperature of the animal laboratory was maintained at 22±1° C. and humidity 55±5%. In addition, the light-dark cycle in the test room was adjusted so that day and night were repeated every 12 hours.

Balb/c 마우스의 복강내에서 1주일간 계대 배양하여 보존하고 있는 육종세포(sarcoma-180)를 시험용 종양세포로 사용하였다. 즉 시험 동물의 복강내에서 1주일간 배양된 sarcoma-180 세포를 복수와 함께 취하고 인산 완충 식염수(phosphate buffered saline:PBS)와 함께 원심분리(1,200rpm, 10min)하여 종양세포를 분리하였다. Sarcoma cells (sarcoma-180) preserved by subculture for 1 week in the peritoneal cavity of Balb/c mice were used as test tumor cells. That is, sarcoma-180 cells cultured for 1 week in the abdominal cavity of the test animal were taken together with ascites, and tumor cells were separated by centrifugation (1,200 rpm, 10 min) together with phosphate buffered saline (PBS).

분리된 세포를 다시 PBS에 부유시켜 재차 원심분리하여 상등액을 제거한 후 1.0×106 cells/㎖가 되도록 종양세포 부유액을 만들어 1㎖씩을 복강 주사하여 이식 보존하면서 시험에 사용하였다.The separated cells were resuspended in PBS, centrifuged again to remove the supernatant, and then a tumor cell suspension was made so that the concentration was 1.0 × 10 6 cells/ml, and 1 ml each was intraperitoneally injected and used for the test while transplant preservation.

시료는 멸균된 PBS를 사용하여 조제하였으며 투여량은 마우스 ㎏당, 40㎎으로 하였다. 투여하지 않을 때는 냉동실에 보관하면서 사용하였다.The sample was prepared using sterilized PBS, and the dose was 40 mg per kg of mouse. When not administered, it was used while being stored in a freezer.

시험동물을 각 군 당 10마리씩으로 하여 시험실에서 1주일 간격으로 계대 보관 중인 종양세포 부유액 0.2㎖(5×106cells/mouse)씩을 시험 동물의 왼쪽 서혜부(left groin)에 피하 이식한 후 일주일 후부터 4주간 매일 1회씩 시료 용액를 복강으로 투여하였다.10 test animals per group, subcutaneously transplanted 0.2㎖ (5×10 6 cells/mouse) of the tumor cell suspension subcutaneously stored in the test room at intervals of 1 week into the left groin of the test animals, and one week later The sample solution was administered intraperitoneally once daily for 4 weeks.

종양세포 이식 35일째 되는 날 치사시켜 생성된 고형암을 적출하고 그 무게를 측정한 후, 다음 수학식 1에 따라 종양 성장 저해율(tumor growth inhibition ratio, IR: %)을 계산하였다.On the 35th day after transplantation of tumor cells, solid tumors produced by killing were removed, their weight was measured, and the tumor growth inhibition ratio (IR: %) was calculated according to Equation 1 below.

<수학식 1><Equation 1>

Figure pat00001
Figure pat00001

(상기 수학식 1에서, Cw는 대조군의 평균 종양 무게이고, Tw는 처리군의 평균 종양 무게이다)(In Equation 1, Cw is the average tumor weight of the control group, and Tw is the average tumor weight of the treatment group)

또한, 시험예 3의 추출물 대신에 멸균 PBS만 투여한 군을 대조군으로 하여 측정 결과를 하기 표 4에 나타내었다.In addition, the measurement results are shown in Table 4 below using the group administered with only sterile PBS instead of the extract of Test Example 3 as a control group.

종양 성장 저해율(%)Tumor growth inhibition rate (%) 대조군 control group 0.8±1.20.8±1.2 실시예 1 생두Example 1 green beans 22.1±1.322.1±1.3 실시예 1 로스팅Example 1 Roasting 22.5±1.222.5±1.2 실시예 2 생두Example 2 green beans 23.2±1.323.2±1.3 실시예 2 로스팅 Example 2 Roasting 23.5±1.323.5±1.3 실시예 3 생두Example 3 Green Beans 25.1±1.125.1±1.1 실시예 3 로스팅Example 3 Roasting 25.2±1.325.2±1.3 실시예 4 생두Example 4 Green Beans 15.1±1.115.1±1.1 실시예 4 로스팅Example 4 Roasting 15.5±1.315.5±1.3 실시예 5 생두Example 5 Green Beans 15.9±1.215.9±1.2 실시예 5 로스팅Example 5 Roasting 15.9±1.415.9±1.4 실시예 6 생두Example 6 Green Beans 15.2±1.315.2±1.3 실시예 6 로스팅Example 6 Roasting 15.3±1.215.3±1.2 실시예 7 생두Example 7 Green Beans 15.1±1.215.1±1.2 실시예 7 로스팅Example 7 Roasting 15.9±1.315.9±1.3 실시예 8 생두Example 8 Green Beans 15.4±1.315.4±1.3 실시예 8 로스팅 Example 8 Roasting 15.9±1.215.9±1.2 실시예 9 생두Example 9 Green Beans 17.1±1.217.1±1.2 실시예 9 로스팅Example 9 Roasting 17.7±1.317.7±1.3 실시예 10 생두Example 10 Green Beans 17.4±1.217.4±1.2 실시예 10 로스팅 Example 10 Roasting 17.9±1.217.9±1.2 실시예 11 생두Example 11 Green Beans 17.4±1.317.4±1.3 실시예 11 로스팅Example 11 Roasting 17.8±1.117.8±1.1 실시예 12 생두Example 12 green beans 19.5±1.319.5±1.3 실시예 12 로스팅Example 12 Roasting 20.2±1.120.2±1.1 실시예 13 생두 Example 13 Green Beans 20.1±1.120.1±1.1 실시예 13 로스팅Example 13 Roasting 19.5±1.219.5±1.2

상기 표 4의 결과를 보면 대조군과 비교하여 본 발명의 추출물에서 종양 성장 억제율이 15% 내지 25% 이르는 것을 확인할 수 있었으며, 복합 종균을 사용할수록 효과가 증가함을 알 수 있었다. 상기 시험 결과로부터 본 발명에 따른 실시예 추출물의 종양 성장 억제효과가 우수함을 알 수 있다.From the results in Table 4, it was confirmed that the tumor growth inhibition rate in the extract of the present invention was 15% to 25% compared to the control group, and the effect increased as the complex spawn was used. From the above test results, it can be seen that the tumor growth inhibitory effect of the example extracts according to the present invention is excellent.

<시험예 5: 세포주를 이용한 면역기능 증강 효과><Test Example 5: Immune Function Enhancement Effect Using Cell Lines>

상기 시험예 1의 면역 기능 증강 효과를 검토하기 위하여 선천성 면역과 후천성 면역의 두반응 모두에 관여하는 면역세포로 특히 비 특이적 면역에 있어 중추적인 역할을 담당하는 대식세포의 활성화를 측정하였다.In order to examine the immune function enhancing effect of Test Example 1, the activation of macrophages, which are immune cells involved in both reactions of innate immunity and acquired immunity, and particularly play a pivotal role in non-specific immunity, was measured.

본 시험에서는 U937 세포(미국 종균협회 ATCC사로부터 입수)를 사용하여 리소좀성 효소(lysosomal enzyme)의 활성 증가를 산 포스파타아제 분석법(acid phosphatase assay: APL)로 측정하였다.In this test, the increase in the activity of lysosomal enzymes was measured by acid phosphatase assay (APL) using U937 cells (obtained from ATCC, Inc., American Growers Association).

시험예 3의 추출물 처리하지 않았을 때의 산 포스파타아제의 활성도를 1로 하여, 처리 농도를 200㎍/㎖로 하였을 때 산 포스파타아제의 활성도를 상대비율을 측정하여 그 결과를 표 5에 나타냈으며, 대조군은 아무 처리도 하지 않은 건조 생두 추출물과 동일한 조건으로 저온 로스팅한 커피 원두 추출물로 하였다.When the activity of acid phosphatase when the extract of Test Example 3 was not treated was set to 1 and the treatment concentration was 200 μg / ml, the relative ratio of the activity of acid phosphatase was measured, and the results are shown in Table 5. The control group was a coffee bean extract roasted at a low temperature under the same conditions as the dried green bean extract without any treatment.

산 포스파타아제 활성도 상대비율Acid phosphatase activity relative ratio 대조군 생두control green beans 0.30.3 대조군 로스팅 원두Control roasted beans 0.30.3 실시예 1 생두Example 1 green beans 1.71.7 실시예 1 로스팅Example 1 Roasting 1.71.7 실시예 2 생두Example 2 green beans 1.61.6 실시예 2 로스팅 Example 2 Roasting 1.81.8 실시예 3 생두Example 3 Green Beans 2.12.1 실시예 3 로스팅Example 3 Roasting 2.02.0 실시예 4 생두Example 4 Green Beans 1.11.1 실시예 4 로스팅Example 4 Roasting 1.31.3 실시예 5 생두Example 5 Green Beans 1.21.2 실시예 5 로스팅Example 5 Roasting 1.21.2 실시예 6 생두Example 6 Green Beans 1.31.3 실시예 6 로스팅Example 6 Roasting 1.21.2 실시예 7 생두Example 7 Green Beans 1.21.2 실시예 7 로스팅Example 7 Roasting 1.31.3 실시예 8 생두Example 8 Green Beans 1.31.3 실시예 8 로스팅 Example 8 Roasting 1.21.2 실시예 9 생두Example 9 Green Beans 1.41.4 실시예 9 로스팅Example 9 Roasting 1.51.5 실시예 10 생두Example 10 Green Beans 1.51.5 실시예 10 로스팅 Example 10 Roasting 1.51.5 실시예 11 생두Example 11 Green Beans 1.41.4 실시예 11 로스팅Example 11 Roasting 1.51.5 실시예 12 생두Example 12 green beans 1.51.5 실시예 12 로스팅Example 12 Roasting 1.41.4 실시예 13 생두 Example 13 Green Beans 1.41.4 실시예 13 로스팅Example 13 Roasting 1.31.3

상기 표 5의 결과를 보면 결과를 보면 대조군과 비교하여 본 발명의 추출물에서 면역기능 증강 효과가 현저하게 상승하는 것을 확인할 수 있었으며, 특히 복합 종균을 사용할수록 효과는 더욱 증가한다.상기 시험 결과로부터 본 발명에 따른 실시예 추출물의 면역기능 증강 효과가 우수함을 알 수 있다.Looking at the results of Table 5, it was confirmed that the immune function enhancing effect was significantly increased in the extract of the present invention compared to the control group. It can be seen that the immune function enhancing effect of the extracts of the examples according to the invention is excellent.

<시험예 6: 시험동물을 이용한 면역기능 증강 효과><Test Example 6: Immune function enhancement effect using test animals>

상기 시험예 3 추출물의 면역 기능 증강 효과를 시험동물 단계에서 검토하였다.The immune function enhancing effect of the extract of Test Example 3 was examined in the test animal stage.

시험동물은 생후 5주된 25~30g의 웅성 Balb/c 마우스를 대한 바이오 링크사로부터 구입하여 사용하였다. 시험 기간 동안 사료와 물은 자유롭게 섭취하도록 하였으며, 동물 시험실의 온도는 22± 1℃, 습도 55± 5%로 유지하였다. As test animals, male Balb/c mice, 5 weeks old and weighing 25 to 30 g, were purchased from Daehan Bio Link and used. Feed and water were freely consumed during the test period, and the temperature of the animal laboratory was maintained at 22±1° C. and humidity 55±5%.

또한, 12시간 마다 낮과 밤이 반복되도록 시험실내 명암주기(light-dark cycle)를 조절하였다.In addition, the light-dark cycle in the test room was adjusted so that day and night were repeated every 12 hours.

시료는 멸균된 생리식염수를 사용하여 조제하였으며 투여량은 마우스 ㎏당, 20㎎으로 하였으며, 투여하지 않을 때는 냉장실에 보관하면서 사용하였다.The sample was prepared using sterilized physiological saline, and the dose was 20 mg per kg mouse, and was used while being stored in a refrigerator when not administered.

시험동물을 각 군당 5마리씩으로 하여 시험실에서 전처리한 시료를 600㎕(1㎎/㎖)씩 매일 복강 주사하였다. 30시간 경과 후 마우스를 단두하여 혈액을 얻고 대식세포는 복강 세척으로 획득하여 시험에 적용하였다.600 μl (1 mg/ml) of the sample pretreated in the test laboratory was intraperitoneally injected every day with 5 animals per group. After 30 hours, the mouse was decapitated to obtain blood, and macrophages were obtained by peritoneal washing and applied to the test.

생쥐 복강에서 회수한 대식세포 수가 1× 106개/㎖ 이 되도록 RPMI-1640 배지에 재분산시키고, 이 분산액을 96-웰 플레이트 각 웰에 200㎕씩 분주한 다음 37℃에서 2시간 동안 CO2 배양하여 대식세포를 웰에 고정시킨 후 각 웰에 RPMI1640 완전배지(with 10% FBS)를 가하여 24시간 동안 배양시킨 후 활성화된 대식세포의 단일층에 0.1% 트리톤(Triton) X-100을 첨가하여 세포막을 용해시켜 이때 분비되는 리소좀성 포스파타아제의 양을 ELISA 판독기(ELISA reader)로 405nm에서 흡광도를 측정하여 대식세포의 활성능 정도를 평가하여 그 결과를 표 6에 나타냈으며, 식염수(saline)를 투여한 군을 대조군으로 하였다. Macrophages recovered from the abdominal cavity of mice were re-dispersed in RPMI-1640 medium to reach 1×10 6 cells/ml, and 200 μl of this dispersion was dispensed into each well of a 96-well plate, followed by CO2 incubation at 37°C for 2 hours. After fixing the macrophages to the wells, RPMI1640 complete medium (with 10% FBS) was added to each well and cultured for 24 hours. was dissolved and the amount of lysosomal phosphatase secreted at this time was measured by the absorbance at 405 nm with an ELISA reader to evaluate the degree of activity of macrophages, and the results are shown in Table 6. The administered group was used as a control group.

대식세포의 활성능Activation of macrophages 대조군 control group 100±1.2100±1.2 실시예 1 생두Example 1 green beans 122.2±1.3122.2±1.3 실시예 1 로스팅Example 1 Roasting 121.5±1.2121.5±1.2 실시예 2 생두Example 2 green beans 123.5±1.3123.5±1.3 실시예 2 로스팅 Example 2 Roasting 123.1±1.3123.1±1.3 실시예 3 생두Example 3 Green Beans 125.1±1.1125.1±1.1 실시예 3 로스팅Example 3 Roasting 125.2±1.3125.2±1.3 실시예 4 생두Example 4 Green Beans 115.4±1.1115.4±1.1 실시예 4 로스팅Example 4 Roasting 115.1±1.3115.1±1.3 실시예 5 생두Example 5 Green Beans 115.6±1.2115.6±1.2 실시예 5 로스팅Example 5 Roasting 115.6±1.4115.6±1.4 실시예 6 생두Example 6 Green Beans 115.2±1.3115.2±1.3 실시예 6 로스팅Example 6 Roasting 115.3±1.2115.3±1.2 실시예 7 생두Example 7 Green Beans 115.1±1.2115.1±1.2 실시예 7 로스팅Example 7 Roasting 115.9±1.3115.9±1.3 실시예 8 생두Example 8 Green Beans 115.4±1.3115.4±1.3 실시예 8 로스팅 Example 8 Roasting 115.9±1.2115.9±1.2 실시예 9 생두Example 9 Green Beans 117.1±1.2117.1±1.2 실시예 9 로스팅Example 9 Roasting 117.7±1.3117.7±1.3 실시예 10 생두Example 10 Green Beans 117.4±1.2117.4±1.2 실시예 10 로스팅 Example 10 Roasting 117.9±1.2117.9±1.2 실시예 11 생두Example 11 Green Beans 117.4±1.3117.4±1.3 실시예 11 로스팅Example 11 Roasting 117.8±1.1117.8±1.1 실시예 12 생두Example 12 green beans 119.5±1.3119.5±1.3 실시예 12 로스팅Example 12 Roasting 120.2±1.1120.2±1.1 실시예 13 생두 Example 13 Green Beans 120.1±1.1120.1±1.1 실시예 13 로스팅Example 13 Roasting 119.5±1.2119.5±1.2

상기 표 6의 결과를 보면 대조군과 비교하여 본 발명의 추출물에서 대식세포의 활성능 증강 효과가 현저하게 상승하는 것을 확인할 수 있었으며, 특히 복합 종균을 사용할수록 효과는 더욱 증가한다.상기 시험 결과로부터 본 발명에 따른 실시예 추출물의 면역기능 증강 효과가 우수함을 알 수 있다.Looking at the results of Table 6, it was confirmed that the effect of enhancing the activity of macrophages in the extract of the present invention was remarkably increased compared to the control group. It can be seen that the immune function enhancing effect of the extracts of the examples according to the invention is excellent.

<시험예 7: 시험 동물을 이용한 체중감소 효과><Test Example 7: Weight loss effect using test animals>

시험동물은 3주령 스프래그 다우리(Sprague-Dawley)종 숫컷 흰쥐를 구입하여 정상 식이 군과 고지방 식이 군 두 군으로 나누었다.As test animals, 3-week-old male Sprague-Dawley rats were purchased and divided into two groups: a normal diet group and a high-fat diet group.

정상 식이 군은 AIN-76A 식이 #100000 (Dyets Inc., Bethlehem, PA, USA)로 식이 총 열량의 11.7%를 지방으로 공급하였고, 고지방 식이 군은 지방 급원으로 우지(beef tallow)를 사용하여 AIN-76 고지방 식이 #100496 (Dyets Inc., Bethlehem, PA, USA)으로 총 열량의 40%를 지방으로 공급하여 사육하였다.The normal diet group supplied 11.7% of the total calories as fat with AIN-76A diet #100000 (Dyets Inc., Bethlehem, PA, USA), and the high-fat diet group used beef tallow as a fat source to provide AIN -76 High-fat diet #100496 (Dyets Inc., Bethlehem, PA, USA) was fed with 40% of total calories as fat.

시험동물 4주령부터 10주령까지 6주간 정상 식이와 고지방 식이를 각각 공급하였으며, 10주령부터 4주간 고지방식이에 시험예 추출물을 각각 식이 무게의 3%를 함유한 식이를 공급하여 효과를 관찰하였다.The test animals were fed a normal diet and a high-fat diet for 6 weeks from 4 weeks of age to 10 weeks of age, and a diet containing 3% of the weight of each test sample extract was supplied to the high-fat diet for 4 weeks from 10 weeks of age to observe the effect. .

시험동물은 한 마리씩 분리하여 사육하였고, 물과 식이는 제한없이 공급하였다. 시험기간 동안 식이 섭취량과 체중은 일주일에 2회 측정하였다. 식이 효율 (Food Efficiency Ratio: FER)은 시험 식이 공급일로부터 희생일까지를 총 시험기간으로 하여 시험기간 동안의 체중 증가량을 시험기간 동안의 식이 섭취량으로 나누어 산출하여 그 결과를 표 7에 나타냈다.The test animals were bred separately one by one, and water and food were supplied without restriction. During the test period, food intake and body weight were measured twice a week. Food efficiency ratio (FER) was calculated by dividing the weight gain during the test period by the food intake during the test period, with the total test period from the test meal supply date to the sacrifice date, and the results are shown in Table 7.

식이 효율dietary efficiency 정상 식이 normal diet 8.148.14 고지방 식이high fat diet 12.1012.10 실시예 1 생두Example 1 green beans 8.048.04 실시예 1 로스팅Example 1 Roasting 8.048.04 실시예 2 생두Example 2 green beans 7.987.98 실시예 2 로스팅 Example 2 Roasting 8.018.01 실시예 3 생두Example 3 Green Beans 7.527.52 실시예 3 로스팅Example 3 Roasting 7.687.68 실시예 4 생두Example 4 Green Beans 8.428.42 실시예 4 로스팅Example 4 Roasting 8.418.41 실시예 5 생두Example 5 Green Beans 8.438.43 실시예 5 로스팅Example 5 Roasting 8.418.41 실시예 6 생두Example 6 Green Beans 8.438.43 실시예 6 로스팅Example 6 Roasting 8.438.43 실시예 7 생두Example 7 Green Beans 8.438.43 실시예 7 로스팅Example 7 Roasting 8.458.45 실시예 8 생두Example 8 Green Beans 8.438.43 실시예 8 로스팅 Example 8 Roasting 8.468.46 실시예 9 생두Example 9 Green Beans 8.178.17 실시예 9 로스팅Example 9 Roasting 8.178.17 실시예 10 생두Example 10 Green Beans 8.188.18 실시예 10 로스팅 Example 10 Roasting 8.208.20 실시예 11 생두Example 11 Green Beans 8.198.19 실시예 11 로스팅Example 11 Roasting 8.218.21 실시예 12 생두Example 12 green beans 8.158.15 실시예 12 로스팅Example 12 Roasting 8.168.16 실시예 13 생두 Example 13 Green Beans 8.158.15 실시예 13 로스팅Example 13 Roasting 8.158.15

상기 표 7의 결과를 보면, 본 발명의 추출물은 대조군의 고지방 식이 보다는 현저하게 체중 증가가 이루어지지 않았으며 거의 대조군의 정상 식이와 유사하였으며, 특히 5종 복합 종균을 사용하는 경우에는 대조군 정상 식이 보다 더 체중이 감소한 결과를 확인할 수 있었다.상기 결과로부터 본 발명 추출물의 현저한 체중 감소 효과를 확인하였다.Looking at the results of Table 7, the extract of the present invention did not significantly increase in weight compared to the high-fat diet of the control group and was almost similar to the normal diet of the control group. The result of further weight loss was confirmed. From the above results, the significant weight loss effect of the extract of the present invention was confirmed.

<시험예 8: 시험 동물을 이용한 지방세포 크기 감소 효과><Test Example 8: Adipocyte size reduction effect using test animals>

시험예 7의 각 시험군에서 16주령이 될 때 각 4마리씩 무작위 추출하여 희생시켜 혈액과 장기를 채취하였다. In each test group of Test Example 7, when they were 16 weeks old, 4 rats were randomly selected and sacrificed, and blood and organs were collected.

지방세포의 평균 크기는 적출한 부고환 지방조직을 가위로 약 30번 정도 자른 후, 4%(wt/vol) 알부민과 1.5 mg/ml 콜라지나제(collagenase)(Sigma, USA)를 함유한 배지 199 (Gibco BRL)에서 37℃에서 60분동안 균질화시킨 후, 현미경을 사용하여 약 30개 세포의 직경을 측정하여 결과값을 구하였으며, 이 결과를 하기 표 8에 나타냈다.The average size of adipocytes was measured by cutting the excised epididymal adipose tissue about 30 times with scissors, then using a medium containing 4% (wt/vol) albumin and 1.5 mg/ml collagenase (Sigma, USA) 199 (Gibco BRL) after homogenization at 37 ° C. for 60 minutes, the diameter of about 30 cells was measured using a microscope to obtain the resulting value, and the results are shown in Table 8 below.

지방세포 크기(㎛)Adipocyte size (㎛) 정상 식이 normal diet 10.73±3.0310.73±3.03 고지방 식이high fat diet 18.72±4.1118.72±4.11 실시예 1 생두Example 1 green beans 8.46±1.158.46±1.15 실시예 1 로스팅Example 1 Roasting 8.44±1.148.44±1.14 실시예 2 생두Example 2 green beans 8.27±1.138.27±1.13 실시예 2 로스팅 Example 2 Roasting 8.34±1.118.34±1.11 실시예 3 생두Example 3 Green Beans 8.07±1.158.07±1.15 실시예 3 로스팅Example 3 Roasting 8.11±1.138.11±1.13 실시예 4 생두Example 4 Green Beans 10.17±1.1510.17±1.15 실시예 4 로스팅Example 4 Roasting 10.13±1.1410.13±1.14 실시예 5 생두Example 5 Green Beans 10.21±1.1510.21±1.15 실시예 5 로스팅Example 5 Roasting 10.17±1.1710.17±1.17 실시예 6 생두Example 6 Green Beans 10.20±1.1510.20±1.15 실시예 6 로스팅Example 6 Roasting 10.19±1.1410.19±1.14 실시예 7 생두Example 7 Green Beans 10.19±1.1410.19±1.14 실시예 7 로스팅Example 7 Roasting 10.22±1.1510.22±1.15 실시예 8 생두Example 8 Green Beans 10.22±1.1510.22±1.15 실시예 8 로스팅 Example 8 Roasting 10.22±1.1610.22±1.16 실시예 9 생두Example 9 Green Beans 9.75±1.129.75±1.12 실시예 9 로스팅Example 9 Roasting 9.74±1.119.74±1.11 실시예 10 생두Example 10 Green Beans 9.81±1.139.81±1.13 실시예 10 로스팅 Example 10 Roasting 9.90±1.119.90±1.11 실시예 11 생두Example 11 Green Beans 9.89±1.119.89±1.11 실시예 11 로스팅Example 11 Roasting 9.84±1.129.84±1.12 실시예 12 생두Example 12 green beans 9.32±1.119.32±1.11 실시예 12 로스팅Example 12 Roasting 9.34±1.129.34±1.12 실시예 13 생두 Example 13 Green Beans 9.30±1.119.30±1.11 실시예 13 로스팅Example 13 Roasting 9.32±1.119.32±1.11

상기 표 8의 결과를 보면, 본 발명의 추출물은 대조군의 고지방 식이 보다는 현저하게 지방세포 크기가 감소하였으며 거의 대조군의 정상 식이와 유사하였으며, 특히 5종 복합 종균을 사용하는 경우에는 대조군 정상 식이 보다 더 감소한 결과를 확인할 수 있었다.상기 결과로부터 본 발명 추출물의 현저한 지방세포 크기 감소 효과를 확인하였다.Looking at the results of Table 8, the extract of the present invention significantly reduced the size of fat cells compared to the high-fat diet of the control group and was almost similar to the normal diet of the control group. The reduction result was confirmed. From the above results, it was confirmed that the extract of the present invention had a significant effect of reducing the size of adipocytes.

<시험예 9 : 혈중 콜레스테롤 함량 변화><Test Example 9: Change in blood cholesterol content>

시험예 8에서 채취한 혈액을 이용하여 콜레스테롤의 함량을 키트(Sigma Chemical Co. (St.Louis, MO))를 이용한 효소비색법으로 측정하여 그 결과를 표 9에 나타냈다.Using the blood collected in Test Example 8, the content of cholesterol was measured by an enzyme colorimetric method using a kit (Sigma Chemical Co. (St. Louis, MO)), and the results are shown in Table 9.

총 콜레스테롤(mg/dl)Total Cholesterol (mg/dl) 정상 식이 normal diet 60.71±1.2160.71±1.21 고지방 식이high fat diet 73.10±1.1173.10±1.11 실시예 1 생두Example 1 green beans 61.24±1.1561.24±1.15 실시예 1 로스팅Example 1 Roasting 61.18±1.1461.18±1.14 실시예 2 생두Example 2 green beans 60.29±1.1360.29±1.13 실시예 2 로스팅 Example 2 Roasting 60.17±1.1160.17±1.11 실시예 3 생두Example 3 Green Beans 58.14±1.1558.14±1.15 실시예 3 로스팅Example 3 Roasting 58.29±1.1358.29±1.13 실시예 4 생두Example 4 Green Beans 67.17±1.1567.17±1.15 실시예 4 로스팅Example 4 Roasting 67.13±1.1467.13±1.14 실시예 5 생두Example 5 Green Beans 67.21±1.1567.21±1.15 실시예 5 로스팅Example 5 Roasting 67.17±1.1767.17±1.17 실시예 6 생두Example 6 Green Beans 67.20±1.1567.20±1.15 실시예 6 로스팅Example 6 Roasting 67.31±1.1467.31±1.14 실시예 7 생두Example 7 Green Beans 66.19±1.1466.19±1.14 실시예 7 로스팅Example 7 Roasting 66.58±1.1566.58±1.15 실시예 8 생두Example 8 Green Beans 66.25±1.1566.25±1.15 실시예 8 로스팅 Example 8 Roasting 66.22±1.1666.22±1.16 실시예 9 생두Example 9 Green Beans 65.75±1.1265.75±1.12 실시예 9 로스팅Example 9 Roasting 65.74±1.1165.74±1.11 실시예 10 생두Example 10 Green Beans 64.81±1.1364.81±1.13 실시예 10 로스팅 Example 10 Roasting 64.90±1.1164.90±1.11 실시예 11 생두Example 11 Green Beans 64.89±1.1164.89±1.11 실시예 11 로스팅Example 11 Roasting 64.84±1.1264.84±1.12 실시예 12 생두Example 12 green beans 63.12±1.1163.12±1.11 실시예 12 로스팅Example 12 Roasting 63.19±1.1263.19±1.12 실시예 13 생두 Example 13 Green Beans 63.30±1.1163.30±1.11 실시예 13 로스팅Example 13 Roasting 63.32±1.1163.32±1.11

상기 표 9의 결과를 보면, 본 발명의 추출물은 대조군의 고지방 식이 보다는 현저하게 총 콜레스테롤 함량이 감소하였으며 거의 대조군의 정상 식이와 유사하였으며, 특히 5종 복합 종균을 사용하는 경우에는 대조군 정상 식이 보다 더 감소한 결과를 확인할 수 있었다.Looking at the results of Table 9, the total cholesterol content of the extract of the present invention was significantly reduced compared to the high-fat diet of the control group and was almost similar to the normal diet of the control group. reduced results were observed.

또한, 침전시약인 덱스트란 설페이트(dextran sulfate) MgCl2 를 이용하여서 LDL과 VLDL을 침전시킨 후 상등액의 콜레스테롤 함량을 키트(Sigma, USA)를 이용하여 비색정량하여 HDL 콜레스테롤을 측정한 본 결과 고지방 식이 군과 실시예 추출물 식이 군에서 차이가 없어 상기 표 9에서의 콜레스테롤 함량 감소는 LDL 콜레스테롤의 감소 따른 것이다.In addition, the precipitation reagent dextran sulfate (dextran sulfate) MgCl 2 After precipitating LDL and VLDL using a kit (Sigma, USA), the cholesterol content of the supernatant was colorimetrically quantified to measure HDL cholesterol. The decrease in cholesterol content in was accompanied by a decrease in LDL cholesterol.

이상에서 살펴본 바와 같이 본 발명은 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 종균으로부터 선택되는 어느 하나 이상의 종균을 커피 생두에 접종 발효하여 코디세핀이 현저하게 증진된 커피 생두를 제조한 다음 이 생두를 추출하여 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 코디세핀을 함유하는 추출물을 제조할 수 있으며, 기본 베이스가 커피이기 때문에 코디세핀을 함유하는 음료 형태로 공급이 가능하여 산업화 및 상업화에 매우 유용하다.As described above, the present invention prepares green coffee beans with markedly enhanced cordycepin by inoculating and fermenting green coffee beans with one or more spawners selected from spawners consisting of Ganoderma lucidum, Phellinus linteus, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis. Then, by extracting the green coffee beans, an extract containing cordycepin showing antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects can be prepared. It is very useful for industrialization and commercialization.

본 발명에 따른 조성물을 복용하는 경우 함량이 증진된 코디세핀에 의해 인간 정상 세포의 면역기능을 활성화하여 암세포의 증식과 재발을 억제하고 혈소판 응집 억제를 통한 항혈전, 항균, 항진균 효과를 얻을 수 있으며, 부수적으로 부드러운 초콜릿 향에 돋보이는 카카오향, 연하고 깊고 풍부한 맛과 향을 느낄 수 있는 장점이 있다.When the composition according to the present invention is taken, the immune function of human normal cells is activated by the increased cordycepin content to inhibit the proliferation and recurrence of cancer cells, and antithrombotic, antibacterial, and antifungal effects can be obtained through inhibition of platelet aggregation, , Incidentally, it has the advantage of being able to feel the cacao scent that stands out with the soft chocolate scent, and the soft, deep and rich taste and aroma.

Claims (10)

영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균을 커피 생두에 접종하여 발효시키는 단계; 및
용매를 물 또는 에탄올로 하여 상기 발효 생두를 추출하는 단계를 포함하는 것을 특징으로 하는 커피와 버섯 균주를 활용한 신규한 코디세핀 함유 추출물 제조방법.
Inoculating green coffee beans with at least one spawn selected from the group consisting of Ganoderma lucidum, Phellinus elegans, chaga, zinnia and cordyceps and fermenting them; and
A novel method for producing a cordycepin-containing extract using coffee and mushroom strains, comprising the step of extracting the fermented green coffee beans using water or ethanol as a solvent.
제 1항에 있어서, 상기 커피 생두는 발아시킨 것임을 특징으로 하는 코디세핀 함유 추출물 제조방법.
The method according to claim 1, wherein the green coffee beans are germinated.
제 1항 또는 제 2항에 있어서, 상기 영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균은 효모균에 접종을 한 후에 20 내지 40℃에서 70 내지 170시간 배양한 것임을 특징으로 하는 코디세핀 함유 추출물 제조방법.
The method of claim 1 or claim 2, wherein at least one spawn selected from the group consisting of Ganoderma lucidum, Sanghwang mushroom, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis is inoculated with yeast and then maintained at 20 to 40 ° C for 70 to 170 hours. Method for producing a cordycepin-containing extract, characterized in that cultured.
제 1항 또는 제 2항에 있어서, 상기 발효는 상기 발효는 온도 20 내지 45℃, 습도 35 내지 70%에서 12 내지 120시간 동안 상기 커피 생두에 접종된 복합 종균을 배양하는 것임을 특징으로 하는 코디세핀 함유 추출물 제조방법.
The cordycepin according to claim 1 or 2, wherein the fermentation is performed by culturing the complex spawn inoculated into the green coffee beans at a temperature of 20 to 45 ° C and a humidity of 35 to 70% for 12 to 120 hours. Method for preparing the containing extract.
제 1항 또는 제 2항에 있어서, 추출단계 전에 상기 커피 생두를 로스팅하는 단계를 더 포함하는 것을 특징으로 하는 코디세핀 함유 추출물 제조방법.
The method for preparing an extract containing cordycepin according to claim 1 or 2, further comprising roasting the green coffee beans before the extraction step.
영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균이 접종 발효되어 코디세핀 함량이 증진된 커피 생두.
Green coffee beans in which cordycepin content is increased by inoculation and fermentation of one or more seed fungi selected from the group consisting of Ganoderma lucidum, Sanghwang mushroom, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis.
제 6항에 있어서, 상기 커피 생두는 발아시킨 것임을 특징으로 하는 코디세핀 함량이 증진된 커피 생두.
The green coffee beans with increased cordycepin content according to claim 6, wherein the green coffee beans are germinated.
영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균이 접종 발효되어 커피 생두를 로스팅하여 제조된 코디세핀 함량이 증진된 커피 원두.
Coffee beans with increased cordycepin content prepared by roasting green coffee beans by inoculating and fermenting at least one spawn selected from the group consisting of Ganoderma lucidum, Sanghwang mushroom, Chaga mushroom, Zinnia mushroom, and Cordyceps sinensis.
영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균을 커피 생두에 접종하여 발효시키는 단계; 및
용매를 물로 하여 상기 발효 생두를 추출하는 단계를 통하여 제조된 추출물을 활성성분으로 포함하여 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 코피세핀을 함유하는 조성물.
Inoculating green coffee beans with at least one spawn selected from the group consisting of Ganoderma lucidum, Phellinus elegans, chaga, zinnia and cordyceps and fermenting them; and
A composition containing cofisepin exhibiting antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects by including the extract prepared through the step of extracting the fermented green coffee beans using water as an active ingredient.
영지버섯, 상황버섯, 차가버섯, 꽃송이버섯 및 동충하초로 이루어진 군에서 선택되는 어느 하나 이상의 종균을 커피 생두에 접종하여 발효시키는 단계;
상기 발효 커피 생두를 로스팅하여 커피 원두를 제조하는 단계: 및
용매를 물 또는 에탄올로 하여 상기 커피 원두를 추출하는 단계를 통하여 제조된 추출물을 활성성분으로 포함하여 항균, 항진균, 면역증강, 항암, 항혈전 효과를 보이는 코피세핀을 함유하는 조성물.
Inoculating green coffee beans with at least one spawn selected from the group consisting of Ganoderma lucidum, Phellinus elegans, chaga, zinnia and cordyceps and fermenting them;
Roasting the fermented green coffee beans to prepare coffee beans: and
A composition containing cofisepin showing antibacterial, antifungal, immune enhancing, anticancer, and antithrombotic effects by including an extract prepared through the step of extracting coffee beans using water or ethanol as an active ingredient.
KR1020210090389A 2021-07-09 2021-07-09 A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient Ceased KR20230009682A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210090389A KR20230009682A (en) 2021-07-09 2021-07-09 A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020210090389A KR20230009682A (en) 2021-07-09 2021-07-09 A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient

Publications (1)

Publication Number Publication Date
KR20230009682A true KR20230009682A (en) 2023-01-17

Family

ID=85111339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210090389A Ceased KR20230009682A (en) 2021-07-09 2021-07-09 A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient

Country Status (1)

Country Link
KR (1) KR20230009682A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102752822B1 (en) 2024-06-24 2025-01-09 이명주 Coffee bean roasting method with improved taste and aroma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010054264A (en) 1999-12-04 2001-07-02 안용준 Cordycepin separated from Cordyceps spp. for an anti-cancer medicine and its production
KR100464876B1 (en) 2001-11-15 2005-01-06 학교법인 인제학원 A composition for preventing formation of thrombosis containing Cordycepin isolated from Cordyceps genus
KR20170049353A (en) 2015-10-28 2017-05-10 주식회사 엘지생활건강 Extraction method of high purity cordycepin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010054264A (en) 1999-12-04 2001-07-02 안용준 Cordycepin separated from Cordyceps spp. for an anti-cancer medicine and its production
KR100464876B1 (en) 2001-11-15 2005-01-06 학교법인 인제학원 A composition for preventing formation of thrombosis containing Cordycepin isolated from Cordyceps genus
KR20170049353A (en) 2015-10-28 2017-05-10 주식회사 엘지생활건강 Extraction method of high purity cordycepin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102752822B1 (en) 2024-06-24 2025-01-09 이명주 Coffee bean roasting method with improved taste and aroma

Similar Documents

Publication Publication Date Title
Bandara et al. Polyporus umbellatus, an edible-medicinal cultivated mushroom with multiple developed health-care products as food, medicine and cosmetics: a review
AU2014233200B2 (en) Myceliated coffee products and methods for making
KR101793123B1 (en) preparing method of fermented soybean enhancing physiological active substance and the physiological active substance thereby
KR101914344B1 (en) A moisturizing and anti-wrinkle cosmetic composition comprising fermented barley, fermented pear juice, fermented soybeans and fermented pomegranate extract and the method preparation of thereof
KR101799424B1 (en) Astragalus membranaceus Fermentation product and its manufacturing method
KR20200054864A (en) Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof
CN103285043B (en) There is the preparation method of the edible fungal protein matter extract of antitumor efficacy
KR102249711B1 (en) Composition for enhancing skin elasticity or improving skin wrinkels comprising enzyme treated extract of leguminous plants cultured root
KR20230009682A (en) A novel method for producing cordycepin using coffee and mushroom strains showing antibacterial, antifungal, immune enhancement, anticancer, and antithrombotic effects, and a composition comprising an extract containing cordycepin produced by the production method as an active ingredient
KR100340663B1 (en) A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use
CN109479613A (en) A kind of composition and its cultural method with ion Victoria C mulberry leaf culture Chinese caterpillar fungus hypha
KR20230010144A (en) A method for preparing an extract containing a large amount of cordycepin and beta-glucan showing various activities including antibacterial, anti-fungal, immune enhancement, anticancer, anti-thrombotic, anti-obesity, blood sugar lowering, and cholesterol reduction using coffee and mushroom strains and multifunctional composition comprising an extract produced by the same preparing metod
KR101549630B1 (en) Composition for improving liver function
KR101385234B1 (en) Manufacturing Method of Fermented Materials for liver function improvement using Acanthopanax sp.
KR20180119940A (en) Method for extract of manufacturing fermentated tea and extract of fermentated tea prepared therefrom
KR100385658B1 (en) A grain culture composition of inonotus obliquus, a method of preparing the antitumor and immuno-activity polysaccharide from it and their use
KR20230010143A (en) A novel method for preparing beta-glucan using coffee and mushroom strains that have the effects of enhancing immunity, anti-cancer, anti-obesity, lowering blood sugar, and lowering blood cholesterol, and a composition comprising the beta-glucan containing extract produced by the method as an active ingredient
KR101053986B1 (en) Production method of callus tissue of Hong Kyung-cheon
KR20170122470A (en) Extract of graviola fermented by phellinus linteus and manufacturing method thereof
KR20010087699A (en) The cultivation method of Cordyceps sinensis et al. having a high concentration of gamma-aminobutyric acid
KR102712026B1 (en) Manufacturing method for composition mycelia, composition mycelia, manufacturing method for material comprising beta-glucan
US20230337597A1 (en) Manufacturing method for composition mycelia, composition mycelia, manufacturing method for material comprising beta-glucan
KR20200081922A (en) Manufacturing method for fermented beverage using ginger, jujube, dried persimmon and strawberry
US20230329269A1 (en) Manufacturing method for beta-glucan-containing coffee and beta-glucan-containing coffee
KR101755338B1 (en) Process for preparation of grifola frondosa fruit body with twice fermentation and functional grifola frondosa fruit body fermentative products

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20210709

PA0201 Request for examination
PN2301 Change of applicant

Patent event date: 20220705

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231019

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240521

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231019

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240521

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20231115

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240617

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20240527

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20240521

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231115

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20231019

X601 Decision of rejection after re-examination